Abstract
Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Current Drug Targets
Title:Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Volume: 14 Issue: 11
Author(s): Sadayuki Hashioka, Tsuyoshi Miyaoka, Rei Wake, Motohide Furuya and Jun Horiguchi
Affiliation:
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Abstract: Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Export Options
About this article
Cite this article as:
Hashioka Sadayuki, Miyaoka Tsuyoshi, Wake Rei, Furuya Motohide and Horiguchi Jun, Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113146660214
DOI https://dx.doi.org/10.2174/13894501113146660214 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Comparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity
Current Topics in Medicinal Chemistry Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases
CNS & Neurological Disorders - Drug Targets LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Pantothenate Kinase-Associated Neurodegeneration
Current Drug Targets The Human Leukocyte Antigen Class III Haplotype Approach: New Insight in Alzheimer's Disease Inflammation Hypothesis
Current Alzheimer Research Oxysterol Derivatives of Cholesterol in Neurodegenerative Disorders
Current Medicinal Chemistry The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Mesenchymal Stromal Cell Secretome: Immunomodulation, Tissue Repair and Effects on Neurodegenerative Conditions
Current Stem Cell Research & Therapy Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Smart Biodegradable Nanoparticulate Materials: Poly-lactide-co-glycolide Functionalization with Selected Peptides
Current Nanoscience Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Recent Patents and Discovery of Anti-inflammatory Agents from Marine Source
Recent Patents on Inflammation & Allergy Drug Discovery Evaluating the Success of the Small Business Innovation Research (SBIR) Program: Impact on Biotechnology Companies in Pennsylvania
Technology Transfer and Entrepreneurship (Discontinued) Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets